Ignite Creation Date:
2024-10-25 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06511739
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-02
Brief Title:
A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo
Detailed Description:
SYHX1901 tablet is being evaluated for the treatment of non-segmental vitiligo The study will enroll approximately 144 participants aged 18-65 with non-segmental vitiligo in 4 treatment arms Participants will either receive study drug vs placebo oral tablets once daily QD for 24 weeks Period A In Period B up to 52 weeks participants who received placebo during the first 24 weeks will switch to study drug Participants who received study drug during the first 24 weeks will continue to receive study drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None